CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 
 

RPRX's Net Income Growth by Quarter and Year

Royalty Pharma Plc's Net Income results by quarter and year




RPRX Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 53.67 477.34 -2.20
III Quarter September 220.41 221.80 624.25 -5.91
II Quarter June 491.60 806.76 601.98 -3.98
I Quarter March 128.08 158.98 -1.62 -4.17
FY   840.09 1,241.21 1,701.95 -16.26



RPRX Net Income third quarter 2022 Y/Y Growth Comment
Royalty Pharma Plc reported decrease in Net Income in the third quarter 2022 by -0.62% to $ 220.41 millions, from the same quarter in 2021.
The decrease in the third quarter 2022 Royalty Pharma Plc's Net Income compares unfavorably to the Company's average Net Income increase of 10.27%.

Looking into third quarter 2022 results within Major Pharmaceutical Preparations industry 34 other companies have achieved higher Net Income growth. While Royalty Pharma Plc' s Net Income decline of -0.62% ranks overall at the positon no. 1334 in the third quarter 2022.




RPRX Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -88.76 % - -
III Quarter September -0.62 % -64.47 % - -
II Quarter June -39.06 % 34.02 % - -
I Quarter March -19.44 % - - -
FY   - -27.07 % - -

Financial Statements
Royalty Pharma Plc's third quarter 2022 Net Income $ 220.41 millions RPRX's Income Statement
Royalty Pharma Plc's third quarter 2021 Net Income $ 221.80 millions Quarterly RPRX's Income Statement
New: More RPRX's historic Net Income Growth >>


RPRX Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -75.8 % -23.53 % -
III Quarter September -55.16 % -72.51 % 3.7 % -
II Quarter June 283.82 % 407.46 % - -
I Quarter March 138.64 % -66.69 % - -
FY (Year on Year)   - -27.07 % - -




Net Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #96
Overall #1334

Net Income Y/Y Growth Statistics
High Average Low
106.4 % 10.27 % -26.04 %
(Sep 30 2020)   (Jun 30 2022)
Net Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #35
Healthcare Sector #96
Overall #1334
Net Income Y/Y Growth Statistics
High Average Low
106.4 % 10.27 % -26.04 %
(Sep 30 2020)   (Jun 30 2022)

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Royalty Pharma Plc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
407.46 % 59.99 % -75.8 %
(Jun 30 2021)  


RPRX's III. Quarter Q/Q Net Income Comment
In the III. Quarter 2022 Royalty Pharma Plc realized fall in Net Income from the second quarter by -55.16% to $ 220.41 millions, from $ 491.60 millions released in the previous reporting period.

If you analyse recent shortcoming in the III. Quarter 2022, you should take into consideration, that usually III. Quarter Net Income occur sluggish then in the preciding period, Aaliyah Davis, market contributor from San Francisco said.

Within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Net Income quarter on quarter growth. While Royalty Pharma Plc's Net Income growth quarter on quarter, overall rank is 2032.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #133
Overall #2032
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #36
Healthcare Sector #133
Overall #2032
Net Income Q/Q Growth Statistics
High Average Low
407.46 % 59.99 % -75.8 %
(Jun 30 2021)  


RPRX's III. Quarter Q/Q Net Income Comment
In the III. Quarter 2022 Royalty Pharma Plc realized fall in Net Income from the previous quarter by -55.16% to $ 220.41 millions, from $ 491.60 millions declared in the previous reporting period.

When you analyse present slump in the quarter, you must presume, that commonly III. Quarter 2022 results appear to be weaker then in the preciding period

Within Major Pharmaceutical Preparations industry 35 other companies have achieved higher Net Income quarter on quarter growth. While Royalty Pharma Plc's Net Income growth quarter on quarter, overall rank is 2032.


Royalty Pharma Plc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Net Income 12 Months Ending $ 893.77 $ 895.15 $ 1,210.31 $ 1,241.20 $ 1,664.87
Y / Y Net Income Growth (TTM) -46.32 % -56.7 % -35.02 % -27.07 % 36.19 %
Year on Year Net Income Growth Overall Ranking # 1592 # 1255 # 1128 # 582 # 917
Seqeuential Net Income Change (TTM) -0.15 % -26.04 % -2.49 % -25.45 % -19.47 %
Seq. Net Income Growth (TTM) Overall Ranking # 1334 # 1387 # 1010 # 703 # 2010




Cumulative Net Income growth Comment
Royalty Pharma Plc showed decline, but improvement compare to trailing twelve month Net Income decrease in Jun 30 2022. If the fiscal year would end in Sep 30 2022, Royalty Pharma Plc's annual Net Income fall would be -46.32% year on year to $894 millions.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 1255 to 1592.

Net Income TTM Q/Q Growth Statistics
High Average Low
106.4 %
10.27 %
-26.04 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 35
Healthcare Sector # 109
Overall # 1592

Net Income TTM Y/Y Growth Statistics
High Average Low
249.06 %
20.02 %
-56.7 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 96
S&P 500 # 1334
Cumulative Net Income growth Comment
Royalty Pharma Plc showed decline, but improvement compare to trailing twelve month Net Income decrease in Jun 30 2022. If the fiscal year would end in Sep 30 2022, Royalty Pharma Plc's annual Net Income drop would be -46.32% year on year to $894 millions.

In the Healthcare sector 108 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 1255 to 1592.

Net Income TTM Q/Q Growth Statistics
High Average Low
106.4 %
10.27 %
-26.04 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 35
Healthcare Sector # 109
Overall # 1592

Net Income TTM Y/Y Growth Statistics
High Average Low
249.06 %
20.02 %
-56.7 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 96
S&P 500 # 1334




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
RPRX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for RPRX's Competitors
Net Income Growth for Royalty Pharma Plc's Suppliers
Net Income Growth for RPRX's Customers

You may also want to know
RPRX's Annual Growth Rates RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons



Companies with similar Net Income drop for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2022
Pediatrix Medical Group Inc -0.19%$ -0.195 millions
Addus Homecare Corporation-0.29%$ -0.294 millions
Royalty Pharma Plc-0.62%$ -0.623 millions
Zoetis Inc -4.35%$ -4.348 millions
Henry Schein Inc -4.41%$ -4.410 millions
Charles River Laboratories International inc -7.18%$ -7.177 millions
Sotera Health Company-8.58%$ -8.577 millions
U S Physical Therapy Inc-9.22%$ -9.219 millions
Ironwood Pharmaceuticals inc -9.90%$ -9.899 millions
Te Connectivity ltd -10.83%$ -10.831 millions
Semler Scientific inc -11.45%$ -11.446 millions
National Research Corporation-14.07%$ -14.073 millions
Lemaitre Vascular Inc-16.11%$ -16.113 millions
Intuitive Surgical Inc -16.14%$ -16.142 millions
Molecular Templates Inc -18.92%$ -18.919 millions
Regeneron Pharmaceuticals Inc -19.39%$ -19.391 millions
Universal Health Services Inc -19.40%$ -19.402 millions
Zynex inc -20.21%$ -20.206 millions
Progyny Inc -21.34%$ -21.344 millions
Khosla Ventures Acquisition Co -22.51%$ -22.507 millions
Tenax Therapeutics Inc -23.22%$ -23.222 millions
Maravai Lifesciences Holdings Inc -24.97%$ -24.966 millions
Reynolds Consumer Products Inc -27.27%$ -27.273 millions
Taitron Components Incorporated-28.61%$ -28.614 millions
Merck and Co Inc -28.83%$ -28.834 millions
Organon and Co -29.72%$ -29.721 millions
Gilead Sciences Inc -30.94%$ -30.936 millions
West Pharmaceutical Services Inc -31.32%$ -31.321 millions
Abbott Laboratories-31.67%$ -31.667 millions
Surgery Partners Inc -31.71%$ -31.707 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CXO's Profile

Stock Price

CXO's Financials

Business Description

Fundamentals

Charts & Quotes

CXO's News

Suppliers

CXO's Competitors

Customers & Markets

Economic Indicators

CXO's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071